Finch Therapeutics Group, Inc. (FNCH)
USD 12.74
(-0.08%)
USD 12.74
(-0.08%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -74.75 Million USD | 34.25% |
| 2022 | -113.69 Million USD | -103.55% |
| 2021 | -55.85 Million USD | -42.32% |
| 2020 | -39.24 Million USD | -92.34% |
| 2019 | -20.4 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -4.83 Million USD | -24.72% |
| 2024 Q1 | -3.87 Million USD | -27.46% |
| 2023 Q3 | -2.41 Million USD | 65.24% |
| 2023 FY | -74.75 Million USD | 34.25% |
| 2023 Q4 | -3.04 Million USD | -25.87% |
| 2023 Q2 | -6.95 Million USD | 89.13% |
| 2023 Q1 | -63.93 Million USD | -142.91% |
| 2022 Q2 | -22.77 Million USD | 7.26% |
| 2022 Q1 | -24.55 Million USD | -28.86% |
| 2022 FY | -113.69 Million USD | -103.55% |
| 2022 Q4 | -26.32 Million USD | 34.38% |
| 2022 Q3 | -40.11 Million USD | -76.15% |
| 2021 FY | -55.85 Million USD | -42.32% |
| 2021 Q4 | -19.05 Million USD | -91.41% |
| 2021 Q3 | -9.95 Million USD | 34.37% |
| 2021 Q1 | -13.98 Million USD | -6.8% |
| 2021 Q2 | -15.16 Million USD | -8.5% |
| 2020 FY | -39.24 Million USD | -92.34% |
| 2020 Q4 | -13.09 Million USD | -29.74% |
| 2020 Q3 | -10.09 Million USD | -22.17% |
| 2020 Q2 | -8.25 Million USD | -4.53% |
| 2020 Q1 | -7.9 Million USD | 0.0% |
| 2019 FY | -20.4 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| America Great Health | -761.42 Thousand USD | -9717.709% |
| Ampio Pharmaceuticals, Inc. | -8.63 Million USD | -766.01% |
| Aridis Pharmaceuticals, Inc. | -30.74 Million USD | -143.11% |
| Biora Therapeutics, Inc. | -124.11 Million USD | 39.77% |
| Bio-Path Holdings, Inc. | -16.07 Million USD | -364.946% |
| Better Therapeutics, Inc. | -39.76 Million USD | -88.013% |
| Calithera Biosciences, Inc. | -18.86 Million USD | -296.237% |
| Comera Life Sciences Holdings, Inc. | -18.37 Million USD | -306.759% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -35.81 Million USD | -108.746% |
| Eloxx Pharmaceuticals, Inc. | -36.06 Million USD | -107.276% |
| Evelo Biosciences, Inc. | -114.52 Million USD | 34.728% |
| Evolutionary Genomics, Inc. | -2.24 Million USD | -3224.971% |
| Galera Therapeutics, Inc. | -59.08 Million USD | -26.526% |
| Innovation1 Biotech Inc. | -5.98 Million USD | -1148.341% |
| Kiromic BioPharma, Inc. | -21.29 Million USD | -251.057% |
| Molecular Templates, Inc. | -8.12 Million USD | -820.162% |
| Navidea Biopharmaceuticals, Inc. | -15.17 Million USD | -392.543% |
| NexImmune, Inc. | -32.34 Million USD | -131.119% |
| Orgenesis Inc. | -55.36 Million USD | -35.03% |
| Panbela Therapeutics, Inc. | -25.26 Million USD | -195.903% |
| Point of Care Nano-Technology, Inc. | -78.01 Thousand USD | -95717.578% |
| PaxMedica, Inc. Common Stock | -18.28 Million USD | -308.721% |
| Scopus BioPharma Inc. | -11.6 Million USD | -543.886% |
| Sorrento Therapeutics, Inc. | -572.84 Million USD | 86.95% |
| Statera Biopharma, Inc. | -174.4 Million USD | 57.138% |
| TRACON Pharmaceuticals, Inc. | -3.58 Million USD | -1983.445% |
| Trevena, Inc. | -40.28 Million USD | -85.544% |
| Vaxxinity, Inc. | -56.93 Thousand USD | -131199.399% |
| Vaccinex, Inc. | -20.25 Million USD | -269.137% |
| Vicapsys Life Sciences, Inc. | -1.18 Million USD | -6223.766% |
| Viracta Therapeutics, Inc. | -51.05 Million USD | -46.41% |
| ZIVO Bioscience, Inc. | -7.77 Million USD | -861.196% |